Raymond Leung

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial

Sanjit S. Jolly, John A. Cairns, Salim Yusuf et al. · The Lancet · 2015 · 222 citations · Full text

Medicine, Cardiology, Surgery +16

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Gregory G. Schwartz, Vera A. Bittner, Patricio López‐Jaramillo et al. · Journal of the American College of Cardiology · 2021 · 141 citations · Full text

Medicine, Cardiology, Pharmacology +17

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek et al. · Circulation · 2022 · 122 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Stroke in the TOTAL trial: a randomized trial of routine thrombectomy vs. percutaneous coronary intervention alone in ST elevation myocardial infarction

Sanjit S. Jolly, John A. Cairns, Salim Yusuf et al. · European Heart Journal · 2015 · 108 citations · Full text

Medicine, Cardiology, Neurology +17